At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 143 enrolled
Drug / intervention
Fosrenol (Lanthanum Carbonate, BAY77-1931) +1 moredrug
Likely dose
Fosrenol (Lanthanum Carbonate, BAY77-1931) 2250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Lanthanum Carbonate 750 to 2250 mg in Patients With Chronic Kidney Disease Not on Dialysis Who Develop Hyperphosphatemia
In Brief
A Phase 3 clinical trial evaluating Fosrenol (Lanthanum Carbonate, BAY77-1931) and Placebo for Hyperphosphatemia. Completed, enrolled 143 participants across 40 sites.
Detailed Summary
The objective of this study is to investigate the efficacy and safety of lanthanum carbonate 750 to 2,250 mg in Japanese Chronic Kidney Disease Stage 3, 4 and 5 subjects not on dialysis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperphosphatemia
CountriesJapan
CollaboratorsShire
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2010
Enrollment StartJun 2010
Primary CompletionNov 2011
TodayJul 2026
First PostedApr 26, 2010
Enrollment StartJun 1, 2010
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 16.2 years ago
Interventions
Fosrenol (Lanthanum Carbonate, BAY77-1931)drug
Daily dose: 750-2250mg 3 times a dayfor 8 weeks.
Placebodrug
daily dose: 3 tablets TID for 8 weeks.